Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

Similar articles for PubMed (Select 20350135)

1.

Prospective association of dopamine-related polymorphisms with smoking cessation in general care.

Breitling LP, Twardella D, Hoffmann MM, Witt SH, Treutlein J, Brenner H.

Pharmacogenomics. 2010 Apr;11(4):527-36. doi: 10.2217/pgs.10.1.

PMID:
20350135
2.

Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation.

David SP, Brown RA, Papandonatos GD, Kahler CW, Lloyd-Richardson EE, Munafò MR, Shields PG, Lerman C, Strong D, McCaffery J, Niaura R.

Nicotine Tob Res. 2007 Aug;9(8):821-33. Erratum in: Nicotine Tob Res. 2007 Nov;9(11):1243.

3.

Association between DRD2/ANKK1 Taq1A genotypes, depression and smoking cessation with nicotine replacement therapy.

Stapleton JA, Sutherland G, O'Gara C, Spirling LI, Ball D.

Pharmacogenet Genomics. 2011 Aug;21(8):447-53. doi: 10.1097/FPC.0b013e328347473a.

PMID:
21540761
4.

Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials.

David SP, Strong DR, Munafò MR, Brown RA, Lloyd-Richardson EE, Wileyto PE, Evins EA, Shields PG, Lerman C, Niaura R.

Nicotine Tob Res. 2007 Dec;9(12):1251-7.

5.

Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch.

Johnstone EC, Yudkin PL, Hey K, Roberts SJ, Welch SJ, Murphy MF, Griffiths SE, Walton RT.

Pharmacogenetics. 2004 Feb;14(2):83-90.

PMID:
15077009
6.

Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion.

David SP, Strong DR, Leventhal AM, Lancaster MA, McGeary JE, Munafò MR, Bergen AW, Swan GE, Benowitz NL, Tyndale RF, Conti DV, Brown RA, Lerman C, Niaura R.

Addiction. 2013 Dec;108(12):2202-11. doi: 10.1111/add.12325. Epub 2013 Sep 18.

7.

Identification of a novel ANKK1 and other dopaminergic (DRD2 and DBH) gene variants in migraine susceptibility.

Ghosh J, Pradhan S, Mittal B.

Neuromolecular Med. 2013 Mar;15(1):61-73. doi: 10.1007/s12017-012-8195-9. Epub 2012 Aug 9.

PMID:
22875483
8.

Dopamine-related genes and spontaneous smoking cessation in ever-heavy smokers.

Breitling LP, Müller H, Illig T, Rujescu D, Winterer G, Dahmen N, Nitz B, Raum E, Rothenbacher D, Brenner H.

Pharmacogenomics. 2011 Aug;12(8):1099-106. doi: 10.2217/pgs.11.74. Epub 2011 Aug 1.

PMID:
21806388
9.

ANKK1/DRD2 locus variants are associated with rimonabant efficacy in aiding smoking cessation: pilot data.

Wilcox CS, Noble EP, Oskooilar N.

J Investig Med. 2011 Dec;59(8):1280-3. doi: 10.231/JIM.0b013e31823581fa.

PMID:
21997315
10.

A DRD2 and ANKK1 haplotype is associated with nicotine dependence.

Voisey J, Swagell CD, Hughes IP, van Daal A, Noble EP, Lawford BR, Young RM, Morris CP.

Psychiatry Res. 2012 Apr 30;196(2-3):285-9. doi: 10.1016/j.psychres.2011.09.024. Epub 2012 Feb 29.

PMID:
22382052
11.

Lack of association of DRD2 rs1800497 (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial.

Munafò MR, Johnstone EC, Murphy MF, Aveyard P.

Nicotine Tob Res. 2009 Apr;11(4):404-7. doi: 10.1093/ntr/ntp007. Epub 2009 Mar 8.

PMID:
19273465
12.

Nicotine dependence as a moderator of genetic influences on smoking cessation treatment outcome.

Leventhal AM, Lee W, Bergen AW, Swan GE, Tyndale RF, Lerman C, Conti DV.

Drug Alcohol Depend. 2014 May 1;138:109-17. doi: 10.1016/j.drugalcdep.2014.02.016. Epub 2014 Mar 5.

13.

Significant association of ANKK1 and detection of a functional polymorphism with nicotine dependence in an African-American sample.

Huang W, Payne TJ, Ma JZ, Beuten J, Dupont RT, Inohara N, Li MD.

Neuropsychopharmacology. 2009 Jan;34(2):319-30. doi: 10.1038/npp.2008.37. Epub 2008 Mar 19.

14.

Pharmacokinetic optimisation of sustained-release bupropion for smoking cessation.

Johnston AJ, Ascher J, Leadbetter R, Schmith VD, Patel DK, Durcan M, Bentley B.

Drugs. 2002;62 Suppl 2:11-24. Review.

PMID:
12109932
15.

Clinical efficacy of bupropion in the management of smoking cessation.

Jorenby D.

Drugs. 2002;62 Suppl 2:25-35. Review.

PMID:
12109933
16.

Changes in food reward following smoking cessation: a pharmacogenetic investigation.

Lerman C, Berrettini W, Pinto A, Patterson F, Crystal-Mansour S, Wileyto EP, Restine SL, Leonard DG, Shields PG, Epstein LH.

Psychopharmacology (Berl). 2004 Aug;174(4):571-7. Epub 2004 Apr 27.

PMID:
15138759
17.

DRD2/ANKK1 TaqI polymorphism and smoking behavior of Egyptian male cigarette smokers.

Radwan GN, El-Setouhy M, Mohamed MK, Hamid MA, Azem SA, Kamel O, Israel E, Loffredo CA.

Nicotine Tob Res. 2007 Dec;9(12):1325-9.

PMID:
18058350
18.

DRD2 genetic variation in relation to smoking and obesity in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Morton LM, Wang SS, Bergen AW, Chatterjee N, Kvale P, Welch R, Yeager M, Hayes RB, Chanock SJ, Caporaso NE.

Pharmacogenet Genomics. 2006 Dec;16(12):901-10.

PMID:
17108814
19.

Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial.

Lerman C, Shields PG, Wileyto EP, Audrain J, Hawk LH Jr, Pinto A, Kucharski S, Krishnan S, Niaura R, Epstein LH.

Health Psychol. 2003 Sep;22(5):541-8.

PMID:
14570538
20.

Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome?

David SP, Niaura R, Papandonatos GD, Shadel WG, Burkholder GJ, Britt DM, Day A, Stumpff J, Hutchison K, Murphy M, Johnstone E, Griffiths SE, Walton RT.

Nicotine Tob Res. 2003 Dec;5(6):935-42.

PMID:
14668077
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk